Aberrant promoter methylation of p16INK4a, RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer

International Journal of Cancer

Volumn 116, Issue 5, 2005, Pages 720-725

  Grote, Hans J ^a   Schmiemann, Viola ^a   Geddert, Helene ^a   Rohr, Ulrich P ^a   Kappes, Rainer ^b   Gabbert, Helmut E ^a   Böcking, Alfred ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Florence Nightingale Krankenhaus   (Germany)

Author keywords

Biomarker; Cytology; Lung cancer; Methylation specific PCR; p16; RARB2; SEMA3B

Indexed keywords

PROTEIN P16INK4A; PROTEIN RARB2; PROTEIN SEMA3B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRONCHUS SECRETION; CONTROLLED STUDY; CPG ISLAND; DISEASE MARKER; FEMALE; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BRONCHI; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RECEPTORS, RETINOIC ACID; SEMAPHORINS; SENSITIVITY AND SPECIFICITY;

EID: 23244436976     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21090     Document Type: Article

References (40)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture, Eur J Cancer 2001;37:4-66.
2. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
4. Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P, Maher ER, Latif F. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast patients. Oncogene 2003;22:147-50.
5. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
6. Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, Shih CM, Chen CY. Inactivation of hMLH1 and hMLH2 by promoter methylation in primary non-small cell lung tumors and matched sputum. J Clin Invest 2003;111:887-95.
7. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
8. Harden SV, Sanderson H, Goodman SN, Partin AA, Walsh PC, Epstein JI, Sidransky D. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 2003;95:1634-7.
9. Chan EC, Lam SY, Tsang KW, Lam B, Ho JC, Fu KH, Lam WK, Kwong YL. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res 2002;8:3741-6.
10. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Williams NN, Kaiser LR, Croce CM. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of Semaphorin 3B in non-small cell lung cancer. Cancer Res 2003;63:3352-5.
11. Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF, Minna JD. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci USA 2001;98:13954-9.
12. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-7.
13. Toyooka S, Maruyama R, Toyooka KO, McLarren D, Feng Z, Fukuyama Y, Virmani AK, Zöchbauer-Müller S, Tsukuda K, Sugio K, Shimizu M, Shimizu K, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153-60.
14. Virmani AK, Rathi A, Zöchbauer-Müller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JG, Gazdar AF. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst 2000; 92:1303-7.
15. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-55.
16. Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J Clin Invest 2002;109:857-62.
17. Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C, Otterson GA. Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene 2001;20:7787-96.
18. Grote HJ, Schmiemann V, Kiel S, Böcking A, Kappes R, Gabbert HE, Sarbia M. Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer. Int J Cancer 2004;110:751-5.
19. Sobin L, Wittekind C. TNM classification of malignant tumours, 5th ed. New York: John Wiley, 1997.
20. Grote HJ, Schmiemann V, Sarbia M, Böcking A. DNA extraction from bronchial aspirates for molecular cytology: which method to take? Anal Cell Pathol 2003;25:83-8.
21. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
22. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
23. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999;59:2302-6.
24. Brabender J, Usadel H. Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park J, Salonga D, Singer J, Sidransky D, et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001;20:3528-32.
25. Topaloglu W, Hoque MO, Tokumaru Y, Lee J, Ratovitski E, Sidransky D, Moon CS. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004;10:2284-8.
26. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J, Sidransky D. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332-9.
27. Chen JT, Chen YC, Wang YC, Tseng RC, Chen CY, Wang YC. Alterations of the p16 (ink4a) gene in resected nonsmall cell lung tumors and exfoliated cells within sputum. Int J Cancer 2002;98:724-31.
28. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, Sidransky D. Gene promoter hypermethylation in tumors and lymph nodes of stage 1 lung cancer patients. Clin Cancer Res 2003;9:1370-5.
29. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ, Kelsey KT. p16INK4a and histology-specific methylation of CpG islands by exposure to tabacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24.
30. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003;94:589-92.
31. Kersting M, Friedl C, Kraus A, Behn M, Pankow W, Schuermann M. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000;18:3221-9.
32. Liu Y, An Q, Li L, Zhang D, Huang J, Feng X, Cheng S, Gao Y. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 2003;24:1897-901.
33. Kurakawa E, Shimamoto T, Utsumi K, Hirano T, Kato H, Ohyashiki K. Hypermethylation of p16(INK4a) and p15 (INK4b) genes in non-small cell lung cancer. Int J Oncol 2001;19:277-81.
34. Waki T, Tamura G, Sato M, Motoyama T. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 2003;22:4128-33.
35. Zöchbauer-Müller S, Lam S, Toyooka S, Virmani AK, Toyooka KO, Seidl S, Minna JD, Gazdar AF. Abberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 2003;107:612-6.
36. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner JF, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
37. Gilliland FD, Harms HJ, Crowell RE, Li YF, Willink R, Belinsky SA. Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16 (INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum. Cancer Res 2002;62:2248-52.
38. Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 2002;62:351-5.
39. Sekido Y, Bader S, Latif F, Chen JY, Duh FM, Wei MH, Albanesi JP, Lee CC, Lerman MI, Minna JD. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci USA 1996;93:4120-55.
40. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-74.